RE: Hold on18 Sep 2025 09:29
Did some research on why Hemogenyx have been invited....
1. They are NY Based and its a Washington/NY summit
2. The agenda suggests that HealthTech is especially highlighted in 2025
3. Other criteria for invitation are as follows:
- Global / cross-border potential: Companies that are working with international partners, scaling beyond single geography, able to collaborate globally.
- Innovation / impact: The solutions should be somewhat transformative, or at least suggest strong potential in terms of impact (policy, environmental, health, etc.).
- Growth readiness / Capital-seekers: Companies likely need to be in a stage where they can benefit from investor exposure (seed, series, scaling companies). Very early pre-product might find it harder The invitations and announcements suggest companies with pipelines, clinical trials are favoured.
- Network / credibility: Might matter who is backing them, previous achievements, ability to engage with policy/regulation, etc. Since policymakers are involved, companies that can show regulatory understanding or relevance may be preferred.
Exciting times - it's hard to imagine that Hemogenyx will not emerge stronger following their participation today